Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials  by Lilenbaum, Rogerio et al.
ORIGINAL ARTICLE
Single-Agent Versus Combination Chemotherapy in
Patients with Advanced Non-small Cell Lung Cancer and a
Performance Status of 2
Prognostic Factors and Treatment Selection Based on Two Large
Randomized Clinical Trials
Rogerio Lilenbaum, MD,* Victoria M. Villaflor, MD,† Corey Langer, MD,‡ Kenneth O’Byrne, MD,§
Mary O’Brien, MD, Helen J. Ross, MD,¶ Mark Socinski, MD,# Fred B. Oldham, MD,**
Larissa Sandilac, MD,** Jack W. Singer, MD,** and Philip Bonomi, MD††
Purpose: Data from two randomized phase III trials were analyzed
to evaluate prognostic factors and treatment selection in the first-line
management of advanced non-small cell lung cancer patients with
performance status (PS) 2.
Patients and Methods: Patients randomized to combination che-
motherapy (carboplatin and paclitaxel) in one trial and single-agent
therapy (gemcitabine or vinorelbine) in the second were included in
these analyses. Both studies had identical eligibility criteria and
were conducted simultaneously. Comparison of efficacy and safety
was performed between the two cohorts. A regression analysis
identified prognostic factors and subgroups of patients that may
benefit from combination or single-agent therapy.
Results: Two hundred one patients were treated with combination
and 190 with single-agent therapy. Objective responses were 37 and
15%, respectively. Median time to progression was 4.6 months in
the combination arm and 3.5 months in the single-agent arm (p 
0.001). Median survival times were 8.0 and 6.6 months, and 1-year
survival rates were 31 and 26%, respectively. Albumin 3.5 g,
extrathoracic metastases, lactate dehydrogenase 200 IU, and 2
comorbid conditions predicted outcome. Patients with 0–2 risk
factors had similar outcomes independent of treatment, whereas
patients with 3–4 factors had a nonsignificant improvement in
median survival with combination chemotherapy.
Conclusion: Our results show that PS2 non-small cell lung cancer
patients are a heterogeneous group who have significantly different
outcomes. Patients treated with first-line combination chemotherapy
had a higher response and longer time to progression, whereas
overall survival did not appear significantly different. A prognostic
model may be helpful in selecting PS 2 patients for either treatment
strategy.
Key Words: NSCLC, Performance status 2, Paclitaxel poliglumex,
Gemcitabine, Vinorelbine, STELLAR, Prognostic model, Combina-
tion chemotherapy, Single-agent chemotherapy.
(J Thorac Oncol. 2009;4: 869–874)
Impaired performance status (PS) in non-small cell lungcancer (NSCLC) is associated with a poor prognosis and
reduced tolerance to treatment. Although current guidelines
support the use of systemic chemotherapy in patients with
advanced NSCLC and PS 2, there is no consensus on specific
treatment recommendations, particularly with respect to sin-
gle-agent versus combination chemotherapy.1,2
Two large phase III randomized trials in advanced
NSCLC patients with PS 2 compared paclitaxel poliglumex
(PGT)/carboplatin to paclitaxel/carboplatin in one study
(STELLAR 3), and single-agent PGT to either vinorelbine or
gemcitabine in the second (STELLAR 4). These studies,
whose results have been published elsewhere,3,4 had identical
eligibility criteria, were conducted simultaneously, and to-
gether represent the largest PS 2 patient population enrolled
in randomized trials to date.
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We conducted a retrospective analysis of these data
to evaluate the efficacy and safety of the two treatment
strategies in the first-line management of advanced NSCLC
patients with PS 2. A regression analysis was conducted to
determine prognostic factors and identify patient subsets
that might benefit from single-agent or combination che-
motherapy.
PATIENTS AND METHODS
Eligibility Criteria and Treatment Plan
The study designs for STELLAR 3 and STELLAR 4
and the patient cohorts analyzed in this report are summarized
in Figure 1. Briefly, STELLAR 3 was a phase III study
comparing paclitaxel 225 mg/m2 with PGT 210 mg/m2, each
in combination with carboplatin (area under the curve  6),
given every 3 weeks for up to 6 cycles. STELLAR 4 was a
phase III comparison of single-agent PGT versus investiga-
tor’s choice of gemcitabine or vinorelbine. At study initiation,
the dose of PGT was 235 mg/m2. As a result of toxicity in the
first 96 patients, the dose of PGT was reduced to 175 mg/m2
in all subsequent patients. PGT was administered on day 1 of
each 21-day cycle for up to 6 cycles. Gemcitabine (1000
mg/m2) was administered on days 1, 8, and 15 of each 28-day
cycle, and vinorelbine (30 mg/m2) was administered on days
1, 8, and 15 of each 21-day cycle. Both studies were con-
ducted in North America, Western, and Eastern Europe be-
tween December 2002 and December 2003 (STELLAR 3),
and December 2002 and June 2004 (STELLAR 4). There was
no duplication of institutions. Both studies were approved by
the institutional review boards and all patients provided
written informed consent.
Eligible patients in both studies had confirmed NSCLC,
an ECOG PS of 2, stage IV or stage IIIB disease not
amenable to combined modality therapy, or recurrent disease
previously treated with radiation and/or surgery. Prior sys-
temic chemotherapy was not permitted. Patients with stable,
treated brain metastases were eligible. Additional eligibility
criteria included a baseline absolute neutrophil count 1500/
l; platelet count 100,000/l; creatinine 1.5 times the
upper limit of normal (ULN); bilirubinULN; transaminases
2.5 times ULN (5 times ULN in patients with hepatic
metastases); and alkaline phosphatase 2.5 times ULN un-
less bone metastases were present.
Statistical Considerations
The primary study end point in both STELLAR 3 and
4 was overall survival. Secondary objectives included re-
sponse rate, assessed by response evaluation criteria in solid
tumors (RECIST5), time to progression (TTP), disease con-
trol, safety, and quality of life. STELLAR 3 targeted accrual
of 370 evaluable patients with 80% power and 0.05 type I
error to show a 1.5-month improvement in median survival
from a projected baseline of 4 to 5.5 months. In STELLAR 4,
the original sample size was 370 patients. After the dose of
PGT was reduced, the randomization ratio was adjusted to
2:1 and an additional 279 patients (185 randomized to PGT
and 94 randomized to the comparator) were accrued, result-
ing in 80% power and 0.05 type I error to detect a 1.5-month
median survival difference between the 2 treatment arms. The
unstratified logrank test was used for the primary comparison
of survival, which included all randomized patients. Toxici-
ties were evaluated in all patients who received any amount
of study drug using the National Cancer Institute Common
Toxicity Criteria, version 2, and were compared using the
Fisher‘s exact test. In both studies, disease-related symptoms
were measured by the Functional Assessment of Cancer
Therapy-Lung Cancer Scale.
This analysis compares efficacy and safety outcomes
for patients treated in the control arms of both studies (“com-
bination chemotherapy”: carboplatin/paclitaxel and “single-
agent therapy”: gemcitabine or vinorelbine). Comparison of
response and toxicity rates between patients treated with
combination chemotherapy versus single agent therapy was
made using the Fisher‘s exact test. Based on the fact that no
statistically significant difference in outcomes was observed
between the control and the experimental arms in both trials,
the regression analysis was performed in the entire population
of STELLAR 3 and 4 to increase the power. The Cox
proportional hazards model was used for identification of
prognostic factors associated with survival and Kaplan-Meier
estimates were used to assess medians and percentiles.
RESULTS
Baseline Characteristics
There were 201 patients in the combination cohort and
190 patients in the single-agent cohort. In the latter, 32
patients received vinorelbine and 155 received gemcitabine.
Patient demographics are shown in Table 1. The majority
of patients were accrued from Eastern European sites. Me-
dian age was 63 and 64, respectively, with approximately
23% of patients aged 70 or older in both groups. Approxi-FIGURE 1. STELLAR 3 and 4 STUDY diagrams.
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mately 27% of the combination cohort and 31% of the
single-agent cohort had stage IIIB disease. Nearly 50% of
patients presented with extrathoracic disease, including 7 and
3%, respectively, with brain metastases. The percentage of
never-smokers ranged from 15 to 18%. For both cohorts, 73
and 80% of the patients had more than 2 comorbid condi-
tions, and 40 and 35%, respectively, had 5% weight loss.
Patient Disposition and Drug Exposure
Patients treated with combination chemotherapy re-
ceived a median of 4 cycles of protocol therapy, with 41% of
patients completing the 6 prescribed cycles. Patients treated
with single-agent therapy received a median of 4 cycles, with
23% of patients completing all 6 cycles. Principal reasons for
discontinuation of protocol therapy were, in the combination
and single-agent groups, respectively, disease progression (34
and 59%) and adverse events (20 and 17%). Dose reductions
were required in 17% of patients in the combination cohort
and 13% of patients receiving single-agent therapy. Hemato-
logic adverse events accounted for the majority of dose
reductions in both the combination cohort and the single-
agent cohort (50 and 68%, respectively).
Toxicity
Overall, grade 3–4 events were recorded in 40% of
patients treated with combination chemotherapy and 22% of
patients treated with single-agent therapy (Table 2). Grade 5
events were noted only in the combination cohort (2%).
Grade 3–4 neutropenia (16%) and thrombocytopenia (7%)
were more frequent in the combination cohort compared
with the single-agent cohort (7% and 1%), while grade
3–4 anemia occurred in about 5% of patients in both
groups. Febrile neutropenia occurred in 2 and 1% of
patients, respectively. Other notable grade 3–4 nonhema-
tological toxicities in the combination versus single-agent
cohorts included nausea (5% versus 1%), diarrhea (4%
versus 0%), and peripheral neuropathy (11% versus 0%).
Median FACT-LCS scores at baseline were 17.0 in both
treatment cohorts; by the end-of-treatment assessment, the
median score had increased to 18.0 in the combination
therapy group but had decreased to 16.5 in the single-agent
treatment group.
Efficacy
Objective partial responses were observed in 38% of
patients with measurable disease treated with combination
chemotherapy, whereas 16% of patients treated with single-
agent therapy experienced an objective response (Table 3).
TABLE 1. Baseline Characteristics by Chemotherapy
Regimen
Combination
(n  201)
Single-Agent
(n  190)
Gender
Male 156 (78%) 134 (70%)
Female 45 (22%) 56 (30%)
Age (years)
Median 63 64
Range 36–89 30–90
Geographic location
United States 45 (22%) 24 (12.6%)
Western Europe and Canada 27 (13%) 25 (13.2%)
Rest of world 129 (64%) 141 (74.2%)
Disease stage at randomization
IIIA 0 2 (1%)
IIIB 55 (27%) 59 (31%)
IV 146 (73%) 129 (68%)
Extrathoracic disease
Yes 108 (56%)a 84 (44%)
No 84 (44%) 104 (55%)
Unknown 0 2 (1%)
History of brain metastases
Yes 15 (7%) 6 (3%)
No 186 (93%) 184 (97%)
Smoking history
Yes 171 (85%) 156 (82%)
No 30 (15%) 34 (18%)
Combination therapy: STELLAR 3, Single-agent therapy: STELLAR 4.
a Extrathoracic disease assessed in 192 patients with measurable disease.
TABLE 2. Number (%) Selected Treatment-Related Adverse Events by Chemotherapy Regimen (Safety
Population)
Combination n  198 Single-Agent n  187
Grade 3/4 Grade 5 Total Grade 3/4 Grade 5 Total
Any AE 79 (39.9%) 3 (2%) 176 (89%) 42 (22.5%) 0 126 (67%)
Neutropenia 31 (15.6%) 0 53 (27%) 13 (7%) 0 25 (13%)
Anemia NOS 9 (4.5%) 0 37 (19%) 10 (5%) 0 46 (25%)
Febrile neutropenia 4 (2%) 1 (1%) 5 (3%) 1 (1%) 0 1 (1%)
Thrombocytopenia 14 (7%) 0 25 (13%) 1 (1%) 0 17 (9%)
Peripheral sensory neuropathy 11 (6%) 0 68 (34%) 0 0 2 (1%)
Fatigue 5 (3%) 0 16 (8%) 5 (3%) 0 22 (12%)
Nausea 10 (5%) 0 70 (35%) 2 (1%) 0 42 (22%)
Diarrhea 7 (4%) 0 25 (13%) 0 0 7 (4%)
Combination therapy: STELLAR 3, Single-agent therapy: STELLAR 4; AE, adverse event.
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Median time to progression was 4.6 months in the combina-
tion cohort and 3.5 months in the single-agent cohort (p 
0.001). Because of the administration schedule, assessment
times for gemcitabine, the treatment most frequently used in
the single-agent cohort, were 2 weeks longer than for vinorel-
bine or combination chemotherapy, which makes an exact
comparison problematic. Median survival times were 8.0
months and 6.6 months, for the combination and the single-
agent cohorts, respectively (Figure 2). One-year survival rates
were 31 and 26% (Table 3). These differences were not
statistically significant.
Median survival on the experimental arm (CT-2103/
carboplatin) of Stellar 3 was 7.8 months, and the 1-year
survival rate was 31%. In Stellar 4, median survival on the
experimental arm (CT-2103) was 7.2 months and the 1-year
survival rate was 26%.
Exploratory Analyses
A regression analysis was performed to identify patient
subsets that may benefit from either combination or single-
agent chemotherapy. A Cox multivariate model using step-
wise selection was then performed, and 4 of the factors
remained significant: albumin 3.5 g (hazard ratio [HR] 1.8;
p  0.0001); extrathoracic metastases (HR 1.5; p  0.0001);
LDH 200 IU (HR 1.4; p  0.0006); and 2 or more
comorbid conditions (HR 1.4; p  0.0014).
Of the 781 evaluable patients enrolled in the 2 trials, 52
(6.7%) had no risk factors; 207 patients (26.7%) had 1; 243
(31.4%) had 2; 143 (18.5%) had 3; and 41 (5.3%) had all 4
risk factors. The median survival times for these 5 subgroups
are shown in Figure 3. Patients were subsequently grouped
into a low-risk (0–2 factors) versus a high-risk subset (3–4
factors). The median survival for the 502 low-risk patients
was 8.8 months compared with 4.8 months for the 184
high-risk patients, with 1-year survival rates of 35 and 15%,
respectively (p  0.001).
When comparing outcome by treatment received, me-
dian survival was identical at 8.8 months in the low-risk
TABLE 3. Efficacy Parameters by Chemotherapy Regimen
Combination Single-Agent
Tumor response (patients with
baseline measurable disease)
n  192 n  179
RECIST criteria–(number/%) with
confirmed and unconfirmed CR/PR
73 (38%) 29 (16%)
Other efficacy parameters n  201 n  190
Disease control (number/%) 138 (69%) 113 (59%)
Median time to progression in
months
4.6 3.6
Median overall survival in months
(95% confidence interval)
8.0 (6.9–9.6) 6.6 (5.8–7.3)
12-mo overall survival
(Kaplan-Meier estimation)
31% 26%
24-mo overall survival
(Kaplan-Meier estimation)
11% 10%
Combination therapy: STELLAR 3, Single-agent therapy: STELLAR 4.
CR, complete response; PR, partial response.
FIGURE 2. Overall survival in days using Kaplan-Meier estimation (combination versus single-agent therapy).
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subset treated with combination chemotherapy or single-
agent therapy, with 1-year survival rates of 37 and 33%,
respectively. In the high-risk subset, median survival was 5.8
months, and 1-year survival was 18% for patients treated with
combination compared with 4.3 months and 13% for patients
treated with single-agent therapy (p  0.2).
Analysis of adverse events in the low-risk versus high-
risk groups showed similar toxicity profiles, with the excep-
tion of more adverse events because of progressive disease in
high-risk patients (53% versus 40%). The rates of grade 3–4
neutropenia (12.2% and 11.5%) and neuropathy (14.8% and
13.7%) grade 2 were similar in the low-risk compared with
the high-risk groups. Tolerability was acceptable overall, and
further subset analysis was not performed on these groups.
DISCUSSION
Patients with a poor PS constitute approximately 30 to
40% of advanced NSCLC patients seen in clinical practice.6
Early data showed that these patients did not seem to benefit
from treatment and experienced a high rate of fatal toxicities
from chemotherapy.7 This resulted in the exclusion of PS 2
patients from cooperative group clinical trials for over a
decade and led to an absence of randomized data or guide-
lines for this subset of patients.
The STELLAR 3 and 4 trials are the largest trials ever
conducted in PS 2 patients with advanced NSCLC. These
trials had identical eligibility criteria and were conducted
simultaneously in similar geographic regions. The patients
enrolled in the control arms of each of the 2 trials were treated
with combination chemotherapy and single-agent therapy,
respectively, and therefore provide a unique opportunity to
assess, within a uniform population, the efficacy and safety of
each approach in the first-line management of PS 2 patients.
Patients treated with combination chemotherapy had a
significantly better response rate and longer time to progres-
sion compared with those treated with single-agent therapy.
Median survival trended in favor of patients treated with
combination chemotherapy but did not reach statistical sig-
nificance. The 1-year survival rates were similar between the
two cohorts. Toxicity, particularly neutropenia and peripheral
neuropathy, was more prevalent in patients treated with
combination chemotherapy. However, the rate of fatal toxic-
FIGURE 3. Overall survival (in days)
by risk. Factors using Kaplan-Meier
estimation (All STELLAR 3 and 4 pa-
tients).
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ities and quality of life parameters were similar in the two
cohorts.
The regression analysis further defined the value of
combination versus single-agent therapy in this subset of
patients. The four risk factors identified in our model, some
of which have also been shown to be of prognostic impor-
tance in patients with PS 0–1,8 were strong predictors of
survival in the PS 2 population analyzed. Further, grouping of
patients based on the number of risk factors showed that in
the low-risk group, combination chemotherapy and single-
agent therapy yielded comparable survival, whereas in the
high-risk group, a trend toward better median survival, rep-
resented by a 1.5-month absolute improvement, was noted in
patients treated with combination chemotherapy. Although
the number of patients in the low-risk subset was sufficiently
robust, the number of patients in the high-risk category was
small and a significant difference cannot be excluded.
Although these data are derived from a retrospective
analysis and therefore should be interpreted with some cau-
tion, they seem to be in agreement with recent clinical trials.
A randomized trial of carboplatin and gemcitabine versus
gemcitabine alone has so far been the only such trial dedi-
cated to PS 2 patients.9 However, it was stopped before
reaching its accrual goal, resulting in loss in statistical power.
In the 170 randomized patients, objective responses were
significantly higher in the combination arm (36.4% versus
11.5%). Progression-free survival was 4.01 versus 2.79
months (p  0.324) and median survival time was 6.9 versus
5.2 months respectively (0.383). Toxicity was worse with the
combination regimen but quality of life scores trended worse
with the single-agent arm. Of interest, baseline LDH level
was also a significant predictor of outcome. A previous
Cancer and Leukemia Group B trial comparing carboplatin-
paclitaxel with single-agent paclitaxel included 99 eligible PS
2 patients and showed a significantly superior response rate,
time to progression, and overall survival for patients treated
with combination chemotherapy.10 Overall, these results are
strikingly similar to our current analysis and lend credence to
the overall conclusions.
Our results show that PS2 NSCLC patients are a het-
erogeneous group who have significantly different outcomes.
Patients treated with first-line combination chemotherapy had
a higher response and longer TTP, whereas overall survival
did not seem significantly different. A prognostic model may
be helpful in selecting PS 2 patients for either treatment
strategy. However, the controversy around the optimal treat-
ment for PS 2 patients with advanced NSCLC remains
unresolved and can only be addressed by prospective ran-
domized clinical trials.
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